Abstract
We revised our hypothesis that the absence of motor behavior impairments at the presymptomatic stage of Parkinsonism, when degeneration of nigrostriatal dopaminergic neurons has already occurred, is the result of compensatory maintenance of a normal extracellular dopamine (DA) concentration in the striatum. We used microdialysis to measure extracellular levels of DA, its precursor L-dihydroxyphenylalanine (L-DOPA), and its metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in mouse striatum in a model of the presymptomatic stage of Parkinsonism. This stage was induced by a single subcutaneous injection of the neurotoxin precursor 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) at a dose of 12 mg/kg. At 14 days after MPTP injection, the extracellular DA content substantially decreased as compared to the control; however, it did not result in alterations of motor behavior, probably due to compensatory processes directed, not to the maintenance of extracellular DA at the normal level, but rather to the elevation of neuronal sensitivity to DA. The extracellular L-DOPA content remained at the normal level. We did not find any changes in the DOPAC and HVA contents.
Thus, degeneration of DA-ergic striatal axons at the presymtomatic stage of Parkinsonism is associated with a decrease in the DA content in the extracellular space. This indicates that activated compensatory mechanisms are not related to the maintenance of DA concentration in the extracellular space but rather to the increased sensitivity of target neurons to DA.
Similar content being viewed by others
References
Ioffe, M.E., Ustinova, K.I., Chernikova, L.A., and Kulikov, M.A., Exp. Brain Res, 2006, vol. 168, pp. 384–394.
Doya, K., J. Neural. Networks, 1999, vol. 12, pp. 961–974.
Roth, R.H and Elsworth, J.D., in Psychopharmacology: The fourth generation of progress, Bloom, F.E. and Kupfer, D.J., Eds., New York: Raven Press, 1995, pp. 227–243.
Buzsaki, G., Smith, A., Berger, S., Fisher, L.J., and Gage, F.H., Neuroscience, 1990, vol. 36, pp. 1–14.
Greengard, P., Allen, P.B., and Nairn, A.C., Neuron, 1999, vol. 23, pp. 435–447.
Kase, H, in Adenosine Receptors and Parkinson’s Disease, Kase, H., Richardson, P., and Jenner, P., Eds., Elsevier Inc. Acad. Press, 2000, pp. 1–15.
Suzuki, T., Miura, M., Nishimura, K., and Aosaki, T., J. Neurosci, 2001, vol. 21, pp. 6492–6501.
Yoshida, M., Rabin, A., and Anderson, M., Brain Res., 1971, vol. 30, pp. 235–239.
Riederer, P. and Wuketich, S., J. Neural. Transm., 1976, vol. 38, pp. 277–301.
Hornykiewicz, O. and Kish, S.J., Adv. Neurol., 1987, vol. 45, pp. 19–34.
Kawaguchi, Y., Wilson, C.J., Augood, S.J., and Emson, P.C., Trends Neurosci., 1995, vol. 18, pp. 527–535.
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., and Seitelberger, F., J. Neurol. Sci., 1973, vol. 20, pp. 415–455.
Bezard, E., Gross, Ch.E., and Brotchie, J.M., Trends Neurosci, 2003, vol. 26, pp. 215–221.
Ugryumov, M.V., Usp. Fiziol. Nauk, 2007, vol. 38, pp. 3–20.
Wu, W.R., Zhu, Z.T., and Zhu, X.Z., Life Sci, 2000, vol. 67, pp. 241–250.
Paxinos, G. and Franklin, K.B.J., The Mouse Brain in Stereotaxic Coordinates, San Diego, San Francisco, New York, Boston, London, Sydney, and Tokyo: Academic Press, 2001.
Averkin, R.G., Korshunov, V.A., Shchegolevskii, N.V., Matz, V.N., Markevich, V.A., Grigor’yan, G.A., and Bazyan, A.S., Zh. Vyssh. Nervn. Deyat, 2009, vol. 59, no. 6, pp. 748–758.
Korshunov, V.A., J. Neurosci. Methods, 2006, vol. 158, pp. 179–185.
Khaindrava, V.G., Kozina, E.A., Kudrin, V.S., Kucheryanu, V.G., and Ugryumov, M.V., Ross. Fiziol. Zhurn. Im. Sechenova, 2009.
Klitenick, M.A., Taber, M.T., and Fibiger, H.C., Neuropsychoparmacol., 1996, vol. 15, pp. 424–428.
You, Z.B., Tzschentke, T.M., Brodin, E., and Wise, R.A., J. Neurosci., 1998, vol. 18, pp. 6492–6500.
You, Z.B., Chen, Y.Q., and Wise, R.A., Neuroscience, 2001, vol. 107, pp. 629–639.
Lin, S.N., Slopis, J.M., Butler, I.J., and Caprioli, R.M., J. Neurosci. Meth., 1995, vol. 62, pp. 199–205.
Shui, H.A., Peng, Y.I., and Tsai, Y.F., Neurosci. Lett., 1998, vol. 257, pp. 1–4.
Ito, M., Nagai, T., Kamei, H., Nakamichi, N., Nabeshima, T., Takuma, K., and Yamada, K., Mol. Pharmacol, 2006, vol. 70, pp. 1720–1725.
Moghaddam, B. and Bunney, B.S., Synapse, 1993, vol. 14, pp. 195–200.
Antonini, A., Schwarz, J., Oertel, W.H., Pogarell, O., and Leenders, K.Z., Mov. Disord., 1997, vol. 12, pp. 33–38.
Verstappen, C.C.P., Bloem, B.R., Haaxma, C.A., Oyen, W.J.G., and Horstink, M.W.I.M., Europ. J. Nucl. Med. Mol. Imaging, 2007, vol. 34, pp. 502–507.
Todd, R.D., Carl, J., Harmon, S., O’Malley, K.L., and Perlmutter, J.S., J. Neurosci., 1996, vol. 16, pp. 7776–7782.
Decamp, E., Wade, T., and Schneider, J.S., Brain Res., 1999, vol. 847, pp. 134–138.
Nikolaus, S., Larisch, R., Beu, M., Forutan, F., Vosberg, H., and Muller-Gartner, H.W., Europ. J. Nucl. Med. Mol. Imaging, 2003, vol. 30, pp. 390–395.
Tanji, H., Araki, T., Nagasawa, H., and Itoyama, Y., Brain Res., 1999, vol. 824, pp. 224–231.
Nacca, A., Li, Q., Vuckovic, M., Leahy, R., Conti, P., Fisher, B., Jakowec, M., and Petzinger, G., J. Nucl. Med, 2008, vol. 49, p. 207.
Joyce, J.N., Woolsey, C., Ryoo, H., Borwege, S., and Hagner, D., BMC, 2004, vol. 2, pp. 22–34.
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Russian Text © Yu.S. Ukraintseva, N.V. Shchegolevskii, V. A. Korshunov, V.G. Kucheryanu, M.V. Ugryumov, A.S. Bazyan, 2010, published in Neirokhimiya, 2010, Vol. 27, No. 2, pp. 164–169.
Rights and permissions
About this article
Cite this article
Ukraintseva, Y.S., Shchegolevskii, N.V., Korshunov, V.A. et al. Modeling of the presymptomatic stage of parkinsonism in mice: Analysis of dopamine release in the striatum. Neurochem. J. 4, 142–147 (2010). https://doi.org/10.1134/S1819712410020108
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1819712410020108